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ABSTRACT 
In order to determine the potency of the test preparation relative to the standard 
preparation, it is often important to test parallelism between a pair of dose-response curves of 
reference standard and test sample. Optimal designs are known to be more powerful in testing 
parallelism as compared to classical designs. In this study, D-optimal design was implemented to 
study the parallelism and compare its performance with a classical design. We modified D-
optimal design to test the parallelism in the four-parameter logistic (4PL) model using 
Intersection-Union Test (IUT). IUT method is appropriate when the null hypothesis is expressed 
as a union of sets, and by using this method complicated tests involving several parameters are 
easily constructed. Since D-optimal design minimizes the variances of model parameters, it can 
bring more power to the IUT test. A simulation study will be presented to compare the empirical 
properties of the two different designs. 
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1. INTRODUCTION 
It is often important for scientists to determine the parallelism between sets of dose-
response data, typically to compare potency of a test preparation relative to a standard 
preparation. For example, decrease or increase in Biomarker concentration is only reliably in 
case parallelism between endogenous Biomarker and concentration-response curve is 
demonstrated. What’s more, parallel testing can increase throughput and reduce test execution. 
The method of testing parallelism will influence the efficiency of the whole process, and 
even the rate of success. Traditionally parallelism test methods are intended for testing equality 
between pairs of parameters between the two dose-response curves. To test the equality, one way 
is to compute the joint conﬁdence region. But it’s complicated when a nonlinear curve model is 
used. Therefore, approximations are made to simplify the task, such as using the intersection of 
marginal conﬁdence intervals as an approximate conﬁdence region (Callahan and Sajjadi, 2003; 
Lansky, 2003). However, this approximation causes the conﬁdence interval to be much larger 
than it should be, resulting in curves being labeled as parallel when they are not.  
The typical procedure to test equality between pairs of parameters is often done by F-test 
that compares the ﬁt of the full (non-parallel) model for the two groups to a reduced (parallel) 
model (Council of Europe, 2011, Finney, 1964). However, it has been criticized as over-sensitive 
to small deviations from parallelism in highly precise assays (Callahan and Sajjadi, 2003, Hauck 
et al., 2005, Gottschalk and Dunn, 2005a). 
Another approach, referred to as equivalence tests, assumes lack of similarity, and seeks 
evidence to prove similarity (see Callahan and Sajjadi 2003 and Hauck et al., 2005). Based on 
the equivalence tests, Berger (1982), Casella and Berger (1990), and Berger and Hsu (1996) gave 
a more complete discussion of Intersection–Union Test(IUT) theory. IUT for practical 
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parallelism is often used in bioequivalence testing, and can be easily implemented by using a 
sequence of one sided approximate t-tests, which can be readily constructed using the output 
from standard nonlinear regression software. It may provide more reliable and satisfying 
inference than the other methods, in the sense that rejecting the null hypothesis establishes 
evidence in favor of practically parallel response curves. So IUT is considered for testing 
parallelism in this research.  
One important factor for the success of testing parallelism is how to design the 
experiment. An optimal design specifies how to distribute resources over doses in the most 
efficient manner and the dose levels at which to take observations. Optimal designs, by 
facilitating the data-collection process and subsequent data analysis in a cost-effective manner, 
are more flexible and efficient, while classical designs require a greater number of experimental 
runs to estimate interesting parameters with the same precision as an optimal design.  
In practical terms, optimal designs can provide accurate statistical inference with 
minimum cost. They minimize the variances of estimating interesting parameters and make 
prediction without bias. Optimal designs use different criteria based on the goal of the 
experiment. In general searching optimal designs for linear models with normal error is not so 
complicate. The Fisher information matrix for a linear model is independent from the model 
parameters, so the optimal designs are obtained in an explicit form. In practical situations, 
however, many natural phenomena follow nonlinear models. Efficient designs for nonlinear 
models are needed in a multitude of application areas. Under nonlinear models, the Fisher 
information matrix depends on the unknown model parameters.  
Searching optimal designs for nonlinear model is a complicated process, so scientists 
usually relied on software to get more accurate outputs. As a software user, it is important to 
3 
 
select an efficient one from all types of algorithms so that the whole computing process can be 
accelerated and the time for algorithm competition can be shortened. Furthermore, choosing a 
proper algorithm can not only prevent the situation that there are special cases in which the 
software won’t work quickly, but also avoid that it will produce unacceptable results.  
Even though there are so many optimal design methods we can use to test parallelism, we 
just studied D-optimal design in this paper. This type of optimal design is constructed to 
minimize the generalized variance of the estimated regression coefficients. D-optimality is a 
powerful experimental design for the determination of parallelism in biological applications, 
because it minimizes the variance of estimating the model parameters and this helps to increase 
the power of IUT test. D-optimal design for logistic models with four parameters was introduced 
by Li and Majumdar (2007). Proper modification is made on the D-optimal design to use it for 
the IUT test. In order to check the performance of the modified D-optimal design, we conduct 
simulation studies to compare the power of IUT test under several scenarios with the design used 
in the paper (Jonkman and Sidik, 2009). 
Section 1 gives introduction about the definition of D-optimal and the motivation of 
using it for testing parallelism. In Section 2, we suggest a simple method of testing the 
hypothesis based on the IUT and explain the algorithm we used to search D-optimal design. Two 
examples that illustrate the procedure of D-optimal design and contrast it with classical design 
are considered in Section 3. A simulation study involving cases based on one of the examples is 
presented and some of the implications of the simulation results are discussed in Section 4. A 
brief discussion and summary is presented in Section 5. 
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2. BACKGROUND 
Parallelism is observed where the dose-response curve of the test sample is a horizontal 
shift of that of the reference standard on the logarithmic dose axis. Mathematically, two 
functions are parallel if one function can be obtained from the other by a scaling of the dose axis. 
2.1. Mathematical function 
Consider the 4-parameter logistic(4PL) model 
Y = 𝑎 +
𝑑−𝑎
1+e[𝑏(𝑐−𝑋)]
+ 𝜀, 𝜀 
𝑖𝑖𝑑
~
 𝑁(0, 𝜎2), 
with unknown 𝜎2, which we have generally found useful in working with drug discovery 
scientists. we typically work in the log base 10 scale for the dose level. Y is the response of 
interest and X is the logarithm of dose of a given preparation. The model has 4 parameters, θ =
(𝑎, 𝑏, 𝑐, 𝑑), where 𝑎 is the lower asymptote of the curve, 𝑑 is the upper asymptote of the curve, 𝑏 
represents the slope of the regression line, and finally𝑐 is the logarithm of the dose corresponding 
to a mean response midway between the lower and upper plateaus. Let 𝑎1, 𝑏1, 𝑐1, 𝑑1 are the 
model parameters for a test group and 𝑎2, 𝑏2, 𝑐2, 𝑑2 are the model parameters for a standard 
group. 
    Consider a test group and a standard group, if 𝑎, 𝑏, 𝑑 are equivalent (i.e., 𝑎1 = 𝑎2, 𝑏1 =
𝑏2, 𝑑1 = 𝑑2), then the horizontal distance between the response curves on the 𝑙𝑜𝑔𝑋 scale is a 
constant 𝑐1 − 𝑐2. Hence the relative potency of the test sample compared to the standard may be 
estimated as 𝑒𝑐1−𝑐2. If the two response curves are not parallel, then the relative potency changes 
depending on the level of response, since the distance between the two curves is not constant. 
Thus, it is standard practice to statistically test the assumption of parallelism prior to estimating 
the relative potency. In this paper, we are interested in accessing the equivalence involving three 
pairs of parameters, and suggest a simple method of testing the hypothesis based on the 
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intersection-union principle (IUT) (see Berger, 1982; Berger and Hsu, 1996; Casella and Berger, 
1990). 
2.2. D-optimal design for four-parameter logistic model 
In the experiments, the goal of optimal design is to make the variances of interesting 
parameters and prediction as small as possible. To minimize the variances, the levels of doses 
and the distribution of subjects over the doses must be decided, depending on how many subjects 
are available and the range of dose levels.  
ξ = (
𝑥1, 𝑥2, … 𝑥𝑠
𝑝1, 𝑝2, … 𝑝𝑠,
) 
A design ξ contains dose levels 𝑥1, 𝑥2, … 𝑥𝑠 and corresponding weights 𝑝1, 𝑝2, … 𝑝𝑠, where 
s ≥ 4, 𝑝𝑡 > 0 and∑ 𝑝𝑡 = 1
𝑠
𝑡=1 . When the total number of doses in the experiment is n, the 
number of replication for dose 𝑥t is 𝑛𝑡, which is the nearest integer of 𝑝𝑡 ∗ 𝑛, 𝑡 = 1,2, … , 𝑠. 
The Fisher information matrix for the 4PL model is 
I(θ, ξ) =  −𝐸 [
𝜕2
𝜕θ ∂θT
𝑙𝑜𝑔𝐿(θ, ξ)], 
where the function L(θ, ξ) is the likelihood function for the data. The information matrix defined 
above is very important in the traditional optimality criteria. This matrix not only depends on the 
design matrix ξ but also the unknown parameters θ. The design matrix ξ is usually chosen to 
optimize certain function of the Fisher information matrix.  
The D-optimality criterion is to choose a design maximizing the information on θ by 
minimizing the generalized variance of its estimate. Denote θ̂ by the maximum likelihood 
estimate of θ, then the asymptotic variance matrix of  θ̂ is the inverse of the Fisher information 
matrix I(θ, ξ). The commonly used D-optimality criterion, which minimizes the generalized 
variance of θ̂, is equivalent to maximize the determinant of the Fisher information matrix, i.e., 
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ξ∗ =
𝑚𝑎𝑥
ξ ∈ 𝐷 𝐷𝑒𝑡 [
𝐼(ξ, 𝜃)
𝑁
] 
where D is the set of all possible designs. Since 𝑁 is a constant, the D-optimality criterion is just 
to maximize the determinant of the Fisher information matrix. Using such an idea,  ξ∗ is the true 
D-optimal design. 
V-algorithm is a general well-known numerical algorithm to obtain locally optimal 
designs and was developed in 1972 (V.V. Fedorov, 1972). The algorithm selects one dose that 
maximizes the sensitive function which is derived from the directional derivative of the optimal 
criterion at each iteration and stops once the design satisfies the Equivalence Theorem (J.M. 
McGree, J.A. Eccleston, and S.B. Duffull, 2008 and F. Pukelsheim, 2006). 
The problem for V-algorithm is that sometimes it takes very long time to converge to the 
locally optimal designs. A state-of-the art algorithm (YBT algorithm) was proposed to find 
locally optimal designs for a single objective and showed that it outperformed to other current 
algorithms including V-algorithm. Starting from a randomly selected initial design, the YBT 
algorithm selects the dose that maximizes the sensitivity function and adds to the previously 
selected designs. At the same time, their optimal weights are obtained directly using the Newton-
Raphson method (K. Quinn, 20016). However, the problem in YBT is that if the selected initial 
design points far from the optimal design points, then the YBT requires a lot more time to 
converge to an optimal design and sometimes it failed to do so. In this paper, the modified YBT 
algorithm was employed to obtain the D-optimal designs (See Hyun, Wong and Yang, 2018). 
The procedure was modified by selecting better starting design points via the V-algorithm, and 
this improved the search speed to obtain the optimal designs (S.W. Hyun, and W.K. Wong. 
Yang, 2013). The modified algorithm performs greatly to obtain all the optimal designs in this 
paper. 
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2.3. Intersection-union test 
In the context of the four-parameter logistic curve, establishing practical equivalence 
enables the assessment of relative potency via the parameters 𝑐1 and 𝑐2. We test whether the 
lower and upper plateaus a and d, and the slope factor b, are equivalent for the test and control 
group. Thus, stating the hypotheses in terms of unions and intersections, we are interested in 
testing 
𝐻0: 
𝑎1 − 𝐷𝐿𝑎2 ≤ 0 𝑜𝑟 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 𝑜𝑟 
𝑏1 − 𝐷𝐿𝑏2 ≤ 0 𝑜𝑟 𝑏1 − 𝐷𝑈𝑏2 ≥ 0 𝑜𝑟
𝑑1 − 𝐷𝐿𝑑2 ≤ 0 𝑜𝑟 𝑑1 − 𝐷𝑈𝑑2 ≥ 0
 
versus 
𝐻1: 
𝑎1 − 𝐷𝐿𝑎2 > 0 𝑎𝑛𝑑 𝑎1 − 𝐷𝑈𝑎2 < 0 𝑎𝑛𝑑 
𝑏1 − 𝐷𝐿𝑏2 > 0 𝑎𝑛𝑑 𝑏1 − 𝐷𝑈𝑏2 < 0 𝑎𝑛𝑑
𝑑1 − 𝐷𝐿𝑑2 > 0 𝑎𝑛𝑑 𝑑1 − 𝐷𝑈𝑑2 < 0
 
where 𝐷𝐿 represent lower limits and 𝐷𝑈 represents upper limits. 
According to the discussion of IUT theory (Berger (1982), Casella and Berger (1990), 
and Berger and Hsu (1996)), this method is useful when the null hypothesis is expressed as a 
union, and the alternative hypothesis is expressed as an intersection. The null hypothesis is true if 
any of component parts are true since it is a union, and if any component of the intersection in 
the alternative is false, the hypothesis is false. Thus, by constructing the test so that each 
component of 𝐻0 is tested separately at level α, and 𝐻0 is rejected only if all the component tests 
reject, the IUT will have at most level α without requiring any multiplicity adjustment. 
2.4. Modified D-optimal design for the IUT test 
ξ𝐷(𝑇) and ξ𝐷(𝐶) works best for estimating model parameters for test and control lines 
respectively, so combing both designs and using them for testing parallelism could be useful. 
ξ𝐷(𝑇) = (
𝑥T1, 𝑥T2, … 𝑥𝑇𝑠
𝑝T1, 𝑝T2, … 𝑝𝑇𝑠
) 
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ξ𝐷(𝐶) = (
𝑥C1, 𝑥C2, … 𝑥𝐶𝑠
𝑝C1, 𝑝C2, … 𝑝𝐶𝑠
) 
Propose ξ𝐷(𝐼𝑈𝑇) = α ∗ ξ𝐷(𝑇) + (1 − 𝛼) ∗ ξ𝐷(𝐶), where α is relative importance of 
ξ𝐷(𝑇) 𝑡𝑜 ξ𝐷(𝐶). Under the assumption both designs are equally important, set α = 0.5. The 
modified D-optimal design ξ𝐷(𝐼𝑈𝑇) is obtained by 
ξ𝐷(𝐼𝑈𝑇) = (
𝑥T1, 𝑥T2, … , 𝑥𝑇𝑠, 𝑥C1, 𝑥C2, … ,  𝑥𝐶𝑠
α𝑝T1, α𝑝T2, … , α𝑝𝑇𝑠, (1 − 𝛼)𝑝T1, (1 − 𝛼)𝑝T2, … , (1 − 𝛼)𝑝𝑇𝑠
), 
If some design points between ξ𝐷(𝑇) and ξ𝐷(𝐶) are overlapped, put only one design point with 
their weight sum (i.e., if 𝑥Ti = 𝑥Cj, them use only 𝑥Ti with corresponding weight α𝑝𝑇𝑖 + (1 −
α)𝑝𝐶𝑗.).  
9 
 
3. TEST FOR PARALLELISM AND EFFICIENT DESIGN 
We statistically test the assumption of parallelism prior to estimating the relative potency, 
since the potency of the test sample compared to the standard is defined simply in terms of the 
parameter 𝑐𝑖 if the response curves for the two preparations are parallel. 
𝐻0: 
𝑎1 − 𝐷𝐿𝑎2 ≤ 0 𝑜𝑟 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 𝑜𝑟 
𝑏1 − 𝐷𝐿𝑏2 ≤ 0 𝑜𝑟 𝑏1 − 𝐷𝑈𝑏2 ≥ 0 𝑜𝑟
𝑑1 − 𝐷𝐿𝑑2 ≤ 0 𝑜𝑟 𝑑1 − 𝐷𝑈𝑑2 ≥ 0
 
versus 
𝐻1: 
𝑎1 − 𝐷𝐿𝑎2 > 0 𝑎𝑛𝑑 𝑎1 − 𝐷𝑈𝑎2 < 0 𝑎𝑛𝑑 
𝑏1 − 𝐷𝐿𝑏2 > 0 𝑎𝑛𝑑 𝑏1 − 𝐷𝑈𝑏2 < 0 𝑎𝑛𝑑
𝑑1 − 𝐷𝐿𝑑2 > 0 𝑎𝑛𝑑 𝑑1 − 𝐷𝑈𝑑2 < 0
, 
𝐷𝐿, 𝐷𝑈 are the equivalence limits, and the choice of the two numbers should be carefully 
considered, based on historical data and information from scientists at the assay laboratory, etc. 
For example, the FDA Division of Bioequivalence (FDA 1992) uses 𝐷𝐿 = 0.8 and 𝐷𝑈 = 1.25 
for bioequivalence hypotheses about ratios. 
For 𝐻01: 𝑎1 − 𝐷𝐿𝑎2 ≤ 0 versus 𝐻11: 𝑎1 − 𝐷𝐿𝑎2 > 0, using a statistic of the form  
𝑇1 =
?̂?1 − 𝐷𝐿?̂?2
𝑠. 𝑒. (?̂?1 − 𝐷𝐿?̂?2)
 
s. e(?̂?1 − 𝐷𝐿?̂?2) = sqrt(var(?̂?1) + 𝐷𝐿
2var(?̂?2)) 
Reject 𝐻01: 𝑎1 − 𝐷𝐿𝑎2 ≤ 0 if 𝑇1 > 𝑡𝑁−8,∝, where N is total sample size, and α is type I 
error rate or significance level. Similarly, for 𝐻02: 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 versus 𝐻12: 𝑎1 − 𝐷𝑈𝑎2 < 0, 
using 𝑇2 =
?̂?1−𝐷𝑈?̂?2
𝑠.𝑒.(?̂?1−𝐷𝑈?̂?2)
, Reject 𝐻02 if 𝑇2 < −𝑡𝑁−8,∝. 
The remaining four tests proceed in analogous fashion. Reject 𝐻0 only if all six one side 
approximate t-test reject 𝐻01, , , , , , 𝐻06 at the same α level (Berger, 1982; Berger and Hsu, 1996; 
Casella and Berger, 1990). 
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Examples given by Dykstra (1971) to illustrate the difference between classical design 
with D-optimal design. One experiment is ten-dose bioassay whose dose-response curves are 
parallelism, with 3 reps, 10 doses and 𝑙𝑜𝑔10(𝑑𝑜𝑠𝑒) ⊂ [1.1, 3.8], and it has a response 𝑌1jk, 𝑗 =
1,2, … ,10, k = 1,2,3. Another experiment is toxicity assay whose dose-response curves are non-
parallelism, with 4 reps, 12 doses, and 𝑙𝑜𝑔10(𝑑𝑜𝑠𝑒) ⊂ [3.5, 9], and it has a response 𝑌2jk, 𝑗 =
1,2, … ,12, k = 1,2,3,4.  
In the ten-dose bioassay, the parameters from Jonkman and Sidik (2009) are  
𝜎1
2 = 𝜎2
2 = 0.042, 𝜖1~𝑁(0, 0.04
2), 𝜖2~𝑁(0, 0.04
2) 
𝑎1 = 2.02, 𝑏1 = −1.42, 𝑐1 = 2.31, 𝑑1 = 10.12; 
 𝑎2 = 2.04, 𝑏2 = −1.35, 𝑐2 = 2.59, 𝑑2 = 9.86. 
Table 1. Classical design for parallel example 
𝑋1j 1.1 1.4 1.7 2.0 2.3 2.6 2.9 3.2 3.5 3.8 
𝑛𝑡 3 3 3 3 3 3 3 3 3 3 
 
This is the classical design, in which 10 doses are equally spaced with equal replication. 𝑋1j is 
logarithm of dose and 𝑛𝑡 is the number of replicated responses. Then, obtained simulated data by 
the 4PL model with the known parameter values to create the Figure 1. For the test line, use 
𝑋1j, 𝑗 = 1,2, … , 10 to generate 𝑌1𝑗𝑘 based on 𝑌1𝑗𝑘 = 2.02 +
10.12−2.02
1+exp [−1.42(2.31−𝑋1j)]
+ 𝜖1𝑗𝑘. For the 
standard line, also use 𝑋1j to get 𝑌
′
1𝑗𝑘 based on the formula 𝑌
′
1𝑗𝑘 = 2.04 +
9.86−2.04
1+exp [−1.35(2.59−𝑋1𝑗)]
+ 𝜖2𝑗𝑘. Set α be equal to 0.05 in this paper.  
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Figure 1. The simulated data and fitted curves for ten-dose bioassay (parallel) 
Used the nonlinear least-squares estimates method to get the estimated parameters based 
on the simulated data. In least square regression, a regression model was established, in which 
the sum of the squares of the vertical distances of different points from the regression curve is 
minimized. Estimated parameters are as follows:  
?̂?1 = 2.08, ?̂?1 = −1.45, ?̂?1 = 10.04, ?̂?2 = 2.06, ?̂?2 = −1.34, ?̂?2 = 10.15 
𝑣𝑎𝑟(?̂?1) = 0.09
2, 𝑣𝑎𝑟(?̂?1) = 0.05
2, 𝑣𝑎𝑟(?̂?1) = 0.11
2 
𝑣𝑎𝑟(?̂?2) = 0.11
2, 𝑣𝑎𝑟(?̂?2) = 0.04
2, 𝑣𝑎𝑟(?̂?2) = 0.09
2 
Test the parallelism using this simulated data. For parameter 𝑎, make an inference as 
follow: 𝐻01: 𝑎1 − 𝐷𝐿𝑎2 ≤ 0 versus 𝐻11: 𝑎1 − 𝐷𝐿𝑎2 > 0. 𝑇1 =
?̂?1−𝐷𝐿?̂?2
𝑠.𝑒.(?̂?1−𝐷𝐿?̂?2)
= 3.58, reject 𝐻01 
since 𝑇1 > 𝑡58,0.05 = 1.67. 𝐻02: 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 versus 𝐻12: 𝑎1 − 𝐷𝑈𝑎2 < 0.𝑇2 =
?̂?1−𝐷𝑈?̂?2
𝑠.𝑒.(?̂?1−𝐷𝑈?̂?2)
=
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−2.94, reject 𝐻02 since 𝑇2 < −𝑡58,0.05 = −1.67. For parameter b, make an inference as follow: 
𝐻01: 𝑏1 − 𝐷𝐿𝑏2 ≤ 0 versus 𝐻11: 𝑏1 − 𝐷𝐿𝑏2 > 0. Reject 𝐻01 since 𝑇1 = 6.32 > 𝑡58,0.05.𝐻02: 𝑏1 −
𝐷𝑈𝑏2 ≥ 0 versus 𝐻12: 𝑏1 − 𝐷𝑈𝑏2 < 0. Reject 𝐻02 since 𝑇2 = −3.10 < −𝑡58,0.05. For parameter 
d, make an inference as follow: 𝐻01: 𝑑1 − 𝐷𝐿𝑑2 ≤ 0 versus 𝐻11: 𝑑1 − 𝐷𝐿𝑑2 > 0. Reject 𝐻01 
since 𝑇1 = 14.34 > 𝑡58,0.05. 𝐻02: 𝑑1 − 𝐷𝑈𝑑2 ≥ 0 versus 𝐻12: 𝑑1 − 𝐷𝑈𝑑2 < 0. Reject 𝐻02 since 
𝑇2 = −16.77 < −𝑡58,0.05. Since all six one side approximate t-test reject 𝐻01, 𝐻02, … , 𝐻06 at the 
0.05 level, the dose-response curves are parallel since all the null hypothesis components are 
rejected. 
Then D-optimal design was motivated for testing parallelism. In Table 2, the first two 
lines show the D-optimal design for the test line, the second two line show the D-optimal design 
for the control line, and the last two lines show the modified D-optimal design for testing the 
parallelism that can be used for fitting both test and control lines. In each design, the first row, X 
represents the dose level in a logarithmic scale and the second row, P represents the proportion 
of subjects at each selected dose level. The proportions of the modified D-optimal design were 
obtained based on the formula 𝑃𝑀 = 0.5 ∗ 𝑃𝑇 + (1 − 0.5) ∗ 𝑃𝐶, where 𝑃𝑇 and 𝑃𝐶 are the proportions 
of subjects in the two different lines, and the number of replicated responses of modified D-
optimal design is 𝑛𝑀, which is the nearest integer of  𝑃𝑀 ∗ 30 , where 30 is the number of subjects 
that are used in test line and control line, respectively. For example, the modified D-optimal 
design assigns seven replications at the first dose level of 1, one replication at the second dose 
level of 1.88, and three replications at the third dose level 1.89, and so on. 
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Table 2. D-optimal design for parallel example 
X 
Test line 
1 1.88 1.89 2.95 4   
𝑃𝑇 0.25 0.08 0.17 0.25 0.25   
X 
Control line 
1 1.99 3.08 4    
𝑃𝐶 0.25 0.25 0.25 0.25    
X 
Modified D-optimal 
1 1.88 1.89 1.99 2.95 3.08 4 
𝑃𝑀 0.25 0.04 0.085 0.125 0.125 0.125 0.25 
𝑛𝑀 7 1 3 4 4 3 8 
 
For the test line, use the modified D-optimal design ξ = (X, 𝑛𝑡) to generate the response 
𝑌1𝑗𝑘 based on 𝑌1𝑗𝑘 = 2.02 +
10.12−2.02
1+exp [−1.42(2.31−𝑋)]
+ 𝜖1𝑗𝑘. For the control line, also use ξ = (X, 𝑛𝑡) 
to get 𝑌′1𝑗𝑘 based on the formula 𝑌
′
1𝑗𝑘 = 2.04 +
9.86−2.04
1+exp [−1.35(2.59−𝑋)]
+ 𝜖2𝑗𝑘. we also used 
nonlinear least-squares to obtain estimated parameters, which are as follows: 
?̂?1 = 1.98, ?̂?1 = −1.41, ?̂?1 = 10.21, ?̂?2 = 2.06, ?̂?2 = −1.36, ?̂?2 = 9.82 
𝑣𝑎𝑟(?̂?1) = 0.03
2, 𝑣𝑎𝑟(?̂?1) = 0.03
2, 𝑣𝑎𝑟(?̂?1) = 0.05
2 
𝑣𝑎𝑟(?̂?2) = 0.09
2, 𝑣𝑎𝑟(?̂?2) = 0.04
2, 𝑣𝑎𝑟(?̂?2) = 0.08
2 
Test the parallelism using this simulated data. For parameter α, make an inference as 
follow: 𝐻01: 𝑎1 − 𝐷𝐿𝑎2 ≤ 0 versus 𝐻11: 𝑎1 − 𝐷𝐿𝑎2 > 0. 𝑇1 =
?̂?1−𝐷𝐿?̂?2
𝑠.𝑒.(?̂?1−𝐷𝐿?̂?2)
= 4.11, reject 𝐻01 
since 𝑇1 > 𝑡58,0.05 = 1.67. 𝐻02: 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 versus 𝐻12: 𝑎1 − 𝐷𝑈𝑎2 < 0.𝑇2 =
?̂?1−𝐷𝑈?̂?2
𝑠.𝑒.(?̂?1−𝐷𝑈?̂?2)
=
−5.02, reject 𝐻02 since 𝑇2 < −𝑡58,0.05 = −1.67. For parameter b, make an inference as follow: 
𝐻01: 𝑏1 − 𝐷𝐿𝑏2 ≤ 0 versus 𝐻11: 𝑏1 − 𝐷𝐿𝑏2 > 0. Reject 𝐻01 since 𝑇1 = 7.60 > 𝑡58,0.05.𝐻02: 𝑏1 −
𝐷𝑈𝑏2 ≥ 0 versus 𝐻12: 𝑏1 − 𝐷𝑈𝑏2 < 0. Reject 𝐻02 since 𝑇2 = −4.87 < −𝑡58,0.05. For parameter 
d, make an inference as follow: 𝐻01: 𝑑1 − 𝐷𝐿𝑑2 ≤ 0 versus 𝐻11: 𝑑1 − 𝐷𝐿𝑑2 > 0. Reject 𝐻01 
since 𝑇1 = 29.05 > 𝑡58,0.05. 𝐻02: 𝑑1 − 𝐷𝑈𝑑2 ≥ 0 versus 𝐻12: 𝑑1 − 𝐷𝑈𝑑2 < 0. Reject 𝐻02 since 
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𝑇2 = −18.59 < −𝑡58,0.05. So the dose-response curves are parallel based on the fact that all the 
null hypothesis components are rejected. 
In the toxicity assay, simulated data in terms of the formula above, and draw Figure 2. 
These parameters also from Jonkman and Sidik (2009) are 
𝜎1
2 = 𝜎2
2 = 1.62, 𝜖1~𝑁(0, 1.6
2), 𝜖2~𝑁(0, 1.6
2) 
𝑎1 = 16.44, 𝑏1 = 0.83, 𝑐1 = 6.35, 𝑑1 = 85.19; 
𝑎2 = 13.61, 𝑏2 = 0.82, 𝑐2 = 6.83, 𝑑2 = 93.01. 
Table 3. Classical design for non-parallelism example from Ding and Bailey (2003) 
𝑋2j 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8 8.5 9.0 
𝑛𝑡 3 3 3 3 3 3 3 3 3 3 3 3 
 
Classical design was applied to test parallelism, in which 12 doses are equally spaced 
with equal replication. 𝑋2j is logarithm of dose and 𝑛𝑡 is the number of dose replication (See 
Ding and Bailey, 2003). For the test line, use 𝑋2j to generate 𝑌2𝑗𝑘 based on 𝑌2𝑗𝑘 = 16.44 +
85.19−16.44
1+exp [0.83(6.35−𝑋2j)]
+ 𝜖1𝑗𝑘 . For the standard line, also use 𝑋2j to obtain response 𝑌
′
2𝑗𝑘 based on 
the formula 𝑌′2𝑗𝑘 = 13.61 +
93.01−13.61
1+exp [0.82(6.83−𝑋2𝑗)]
+ 𝜖2𝑗𝑘. Draw the simulated data to create the 
Figure 2. 
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Figure 2. The simulated data and fitted curves for toxicity(non-parallel) 
For this classical design, we also used nonlinear least-squares to estimate the parameters 
based on simulated data, which are shown as follows:  
?̂?1 = 17.51, ?̂?1 = 0.85, ?̂?1 = 84.17, ?̂?2 = 12.96, ?̂?2 = 0.81, ?̂?2 = 92.71 
𝑣𝑎𝑟(?̂?1) = 1.60
2, 𝑣𝑎𝑟(?̂?1) = 0.06
2, 𝑣𝑎𝑟(?̂?1) = 1.75
2 
𝑣𝑎𝑟(?̂?2) = 2.04
2, 𝑣𝑎𝑟(?̂?2) = 0.08
2, 𝑣𝑎𝑟(?̂?2) = 3.58
2 
Then, the parallelism was also tested with classical design by using these new simulated 
data. For parameter α, make an inference as follow: 𝐻01: 𝑎1 − 𝐷𝐿𝑎2 ≤ 0 versus 𝐻11: 𝑎1 −
𝐷𝐿𝑎2 > 0. 𝑇1 =
?̂?1−𝐷𝐿?̂?2
𝑠.𝑒.(?̂?1−𝐷𝐿?̂?2)
= 3.12, reject 𝐻01 since 𝑇1 > 𝑡64,0.05 = 1.67. 𝐻02: 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 
versus 𝐻12: 𝑎1 − 𝐷𝑈𝑎2 < 0. 𝑇2 =
?̂?1−𝐷𝑈?̂?2
𝑠.𝑒.(?̂?1−𝐷𝑈?̂?2)
= 0.44, fail to reject 𝐻02 since 𝑇2 > −𝑡64,0.05 =
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−1.67. For parameter b, make an inference as follow: 𝐻01: 𝑏1 − 𝐷𝐿𝑏2 ≤ 0 versus 𝐻11: 𝑏1 −
𝐷𝐿𝑏2 > 0. Since 𝑇1 = 2.29 > 𝑡64,0.05, reject 𝐻01. 𝐻02: 𝑏1 − 𝐷𝑈𝑏2 ≥ 0 versus 𝐻12: 𝑏1 − 𝐷𝑈𝑏2 <
0. Fail to reject 𝐻02 since 𝑇2 = −1.38 > −𝑡64,0.05. For parameter d, make an inference as 
follow: 𝐻01: 𝑑1 − 𝐷𝐿𝑑2 ≤ 0 versus 𝐻11: 𝑑1 − 𝐷𝐿𝑑2 > 0. Reject 𝐻01 since 𝑇1 = 2.98 > 𝑡64,0.05. 
𝐻02: 𝑑1 − 𝐷𝑈𝑑2 ≥ 0 versus 𝐻12: 𝑑1 − 𝐷𝑈𝑑2 < 0. Reject 𝐻02 since 𝑇2 = −6.61 < −𝑡64,0.05. The 
dose-response curves are non-parallel because not all null hypothesizes are rejected.  
We got the D-optimal design for the two lines and the modified D-optimal design in 
Table 4. In this example, total of 36 responses are used to fit both lines, so the number of 
replicated responses of modified D-optimal design  𝑛𝑀 is obtained by the nearest integer of  𝑃𝑀 ∗
36. From Table 4, we found modified D-optimal design has 6 selected dose levels and the 
number of replications are varied at each dose levels.  
Table 4. D-optimal design for non-parallel example 
X 
Test line 
3.5 5.35 7.25 9    
𝑃𝑇 0.25 0.25 0.25 0.25    
X 
Control line 
3.5 5.56 7.46 9    
𝑃𝐶 0.25 0.25 0.25 0.25    
X 
Modified D-optimal 
3.5 5.35 5.56 7.25 7.46 9  
𝑃𝑀 0.25 0.125 0.125 0.125 0.125 0.25  
𝑛𝑀 9 4 5 5 4 9  
 
Then, D-optimal design was applied to test parallelism. For the test line, use X to generate 
𝑌2𝑗𝑘 based on 𝑌1𝑗𝑘 = 16.44 +
85.19−16.44
1+exp [0.83(6.35−X)]
+ 𝜖1𝑗𝑘. For the standard line, also use X to 
obtain response 𝑌′2𝑗𝑘 based on the formula 𝑌
′
2𝑗𝑘 = 13.61 +
93.01−13.61
1+exp [0.82(6.83−X)]
+ 𝜖2𝑗𝑘. Estimated 
parameters were obtained, which are as follows: 
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?̂?1 = 14.34, ?̂?1 = 0.76, ?̂?1 = 87.05, ?̂?2 = 12.86, ?̂?2 = 0.76, ?̂?2 = 95.24 
𝑣𝑎𝑟(?̂?1) = 1.45
2, 𝑣𝑎𝑟(?̂?1) = 0.05
2, 𝑣𝑎𝑟(?̂?1) = 1.63
2 
𝑣𝑎𝑟(?̂?2) = 1.06
2, 𝑣𝑎𝑟(?̂?2) = 0.04
2, 𝑣𝑎𝑟(?̂?2) = 2.01
2 
Test the parallelism using this simulated data. For parameter α, make an inference as 
follow: 𝐻01: 𝑎1 − 𝐷𝐿𝑎2 ≤ 0 versus 𝐻11: 𝑎1 − 𝐷𝐿𝑎2 > 0. 𝑇1 = 2.41, reject 𝐻01 since 𝑇1 >
𝑡58,0.05 = 1.67. 𝐻02: 𝑎1 − 𝐷𝑈𝑎2 ≥ 0 versus 𝐻12: 𝑎1 − 𝐷𝑈𝑎2 < 0.𝑇2 = −0.88, fail to reject 𝐻02 
since 𝑇2 > −𝑡58,0.05 = −1.67. For parameter b, make an inference as follow: 𝐻01: 𝑏1 − 𝐷𝐿𝑏2 ≤
0 versus 𝐻11: 𝑏1 − 𝐷𝐿𝑏2 > 0. Reject 𝐻01 since 𝑇1 = 2.58 > 𝑡58,0.05.𝐻02: 𝑏1 − 𝐷𝑈𝑏2 ≥ 0 versus 
𝐻12: 𝑏1 − 𝐷𝑈𝑏2 < 0. Reject 𝐻02 since 𝑇2 = −2.65 < −𝑡58,0.05. For parameter d, make an 
inference as follow: 𝐻01: 𝑑1 − 𝐷𝐿𝑑2 ≤ 0 versus 𝐻11: 𝑑1 − 𝐷𝐿𝑑2 > 0. Reject 𝐻01 since 𝑇1 =
4.74 > 𝑡58,0.05. 𝐻02: 𝑑1 − 𝐷𝑈𝑑2 ≥ 0 versus 𝐻12: 𝑑1 − 𝐷𝑈𝑑2 < 0. Reject 𝐻02 since 𝑇2 =
−10.69 < −𝑡58,0.05. So the dose-response curves are non-parallel based on the fact that not all 
the null hypothesis components are rejected. The results are summarized in Table 5. 
As seen from Table 5, based on the results of the proposed test, the toxicity assay with 
two designs both do not provide compelling evidence that the response profiles are in fact 
parallel. While comparing the t value with critical value (𝑡58,0.05 = 1.67), it appears that the 
slopes and the plateaus are practically equivalent, and thus that the response profiles may be 
considered parallel. What’s more, the fact that absolute t value for D-optimal design is always 
larger and it shows that it benefits the experimenter more for improving the precision of the 
assay. 
In first example, inspection of Figure 1 suggests that the response profiles are 
approximately parallel. Testing parallelism with the two design methods both indicated that 
response lines are parallel. In contrast to the preceding example, the plot does give some 
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indication of non-parallel the second example response profiles, as the horizontal distance 
between the test observations and the standard observations appears to decrease somewhat as the 
response level increases. In order to validate the outperformance of the modified optimal design 
on the IUT test, we conduct simulation studies under several different scenarios.  
Table 5. T value results for the two examples 
Parameter Estimate SE T value for test 
using 𝐷𝐿 
T value for test 
using 𝐷𝑈 
Ten-dose bioassay(parallel) with classical design 
𝑎1 2.08 0.09 3.58 -2.94 
𝑎2 2.06 0.11 
𝑏1 -1.45 0.05 6.32 -3.10 
𝑏2 -1.34 0.04 
𝑑1 10.04 0.11 14.34 -16.77 
𝑑2 10.15 0.09 
Ten-dose bioassay(parallel) with modified D-optimal design 
𝑎1 1.98 0.03 4.11 -5.02 
𝑎2 2.06 0.09 
𝑏1 -1.41 0.03 7.60 -4.87 
𝑏2 -1.36 0.04 
𝑑1 10.21 0.05 29.05 -18.59 
𝑑2 9.82 0.08 
Toxicity assay (non-parallel) with classical design 
𝑎1 17.51 1.60 3.12 0.44 
𝑎2 12.96 2.04 
𝑏1 0.85 0.06 2.29 -1.38 
𝑏2 0.81 0.08 
𝑑1 84.17 1.75 2.98 -6.61 
𝑑2 92.71 3.58 
Toxicity assay (non-parallel) with modified D-optimal design 
𝑎1 14.34 1.45 2.41 -0.88 
𝑎2 12.86 1.06 
𝑏1 0.76 0.05 2.58 -2.65 
𝑏2 0.76 0.04 
𝑑1 87.05 1.63 4.74 -10.69 
𝑑2 95.24 2.01 
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4. SIMULATION STUDY 
Previous section shows some insight of the benefit of using D-optimal design for the IUT 
test. To assess more precise properties of the D-optimal design over the classical design method 
for testing the parallelism, we performed a simulation study based on the same simulation set-up 
in Jonkman and Sidik, 2009. The paper conduct simulation studies for testing parallelism under 5 
different scenarios: 
1. A case set 𝑎1 = 2.02, 𝑏1 = −1.42, 𝑐1 = 2.31, 𝑑1 = 10.12 for the test preparation, 
and 𝑎2 = 2.04, 𝑏2 = −1.35, 𝑐2 = 2.59, 𝑑2 = 9.86 for the standard preparation. The curves for 
the test and standard preparations are approximately parallel: that is, a case in which all three 
ratios are within the 𝐷𝐿𝑎𝑛𝑑 𝐷𝑈. For this, 𝑎1, 𝑏1, 𝑐1, 𝑑1, 𝑎2, 𝑏2, 𝑐2, 𝑑2are set equal to the parameter 
estimates from the example of section 3.  
2. A case set 𝑎1 = 2.0, 𝑏1 = −1.4, 𝑐1 = 2.3, 𝑑1 = 10.0 for the test preparation, and 𝑎2 =
2.0, 𝑏2 = −1.4, 𝑐2 = 2.6, 𝑑2 = 10.0 for the standard preparation. The curves are exactly parallel, 
and the only difference is the potency. Values 𝑎1, 𝑏1, 𝑐1, 𝑑1, 𝑎2, 𝑏2, 𝑐2, 𝑑2 are close to those from 
the example of section 3. 
3. A case set 𝑎1 = 1.6, 𝑏1 = −1.5, 𝑐1 = 2.3, 𝑑1 = 8.0 for the test preparation, and 𝑎2 =
2.0, 𝑏2 = −1.2, 𝑐2 = 2.6, 𝑑2 = 10.0 for the standard preparation. The ratios for the plateaus and 
the slope are all on the boundary for the equivalence test: that is, 
𝑎1
𝑎2
= 𝐷𝐿 = 0.8, 
𝑏1
𝑏2
= 𝐷𝑈 =
1.25, and 
𝑑1
𝑑2
= 𝐷𝐿 = 0.8.  
4. A case set 𝑎1 = 1.5, 𝑏1 = −1.4, 𝑐1 = 2.3, 𝑑1 = 10.0 for the test preparation, and 𝑎2 =
2.0, 𝑏2 = −1.4, 𝑐2 = 2.6, 𝑑2 = 10.0 for the standard preparation. The ratio of the lower plateaus 
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is outside the equivalence limits for the IUT (
𝑎1
𝑎2
< 𝐷𝐿), but the slopes and the upper plateaus are 
equal.  
5. A case set 𝑎1 = 2.0, 𝑏1 = −1.5, 𝑐1 = 2.3, 𝑑1 = 10.0 for the test preparation, and 𝑎2 =
2.0, 𝑏2 = −1.16, 𝑐2 = 2.6, 𝑑2 = 10.0 for the standard preparation. The ratio of the slopes is 
outside the equivalence limits for the IUT (
𝑏1
𝑏2
> 𝐷𝑈), but both plateaus are equal.  
At the first part, we considered the classical design in Table 1 to simulate the responses. 
Next, tested whether the dose-response curves are parallelism or not separately by IUT. Then we 
run this 10000 times to calculate the power of detecting the parallelism via IUT. The 
investigation was conducted in the same way for the above five cases. 
At the second part, repeated all the steps in the previous part using the modified D-
optimal design instead of the standard design. The "VNM" package in R was performed to obtain 
multiple-objective optimal design. The MOPT function was used to maximize the optimality 
criterion and verify the optimality of the generated design using the General Equivalence 
Theorem (See Hyun, Wong and Yang).  
All the obtained D-optimal designs and the modified D-optimal design for each case are 
given in Table 6, 7, 8, 9, and 10. 
Table 6. Modified D-optimal design for two lines in case 1 
X 
Control line 
1 1.88 1.89 2.95 4   
𝑃𝐶 0.25 0.08 0.17 0.25 0.25   
X 
Test line 
1 1.99 3.08 4    
𝑃𝑇 0.25 0.25 0.25 0.25    
X 
Modified D-
optimal 
1 1.88 1.89 1.99 2.95 3.08 4 
𝑃𝑀 0.25 0.04 0.085 0.125 0.125 0.125 0.25 
𝑛𝑀 7 1 3 4 4 3 8 
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Table 7. Modified D-optimal design for two lines in case 2 
X 
Control line 
1 1.88 2.95 4   
𝑃𝐶 0.25 0.25 0.25 0.25   
X 
Test line 
1 2.01 3.08 4   
𝑃𝑇 0.25 0.25 0.25 0.25   
X 
Modified D-optimal 
1 1.88 2.01 2.95 3.08 4 
𝑃𝑀 0.25 0.125 0.125 0.125 0.125 0.25 
𝑛𝑀 7 4 4 4 3 8 
 
Table 8. Modified D-optimal design for two lines in case 3 
X 
Control line 
1 1.88 2.93 4   
𝑃𝐶 0.25 0.25 0.25 0.25   
X 
Test line 
1 1.97 3.1 4   
𝑃𝑇 0.25 0.25 0.25 0.25   
X 
Modified D-optimal 
1 1.88 1.97 2.93 3.1 4 
𝑃𝑀 0.25 0.125 0.125 0.125 0.125 0.25 
𝑛𝑀 7 4 4 4 3 8 
 
Table 9. Modified D-optimal design for two lines in case 4 
X 
Control line 
1 1.88 2.95 4   
𝑃𝐶 0.25 0.25 0.25 0.25   
X 
Test line 
1 2.01 3.08 4   
𝑃𝑇 0.25 0.25 0.25 0.25   
X 
Modified D-optimal 
1 1.88 2.01 2.95 3.08 4 
𝑃𝑀 0.25 0.125 0.125 0.125 0.125 0.25 
𝑛𝑀 7 4 4 4 3 8 
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Table 10. Modified D-optimal design for two lines in case 5 
X 
Control line 
1 1.88 2.93 4   
𝑃𝐶 0.25 0.25 0.25 0.25   
X 
Test line 
1 1.96 3.1 4   
𝑃𝑇 0.25 0.25 0.25 0.25   
X 
Modified D-optimal 
1 1.88 1.96 2.93 3.1 4 
𝑃𝑀 0.25 0.125 0.125 0.125 0.125 0.25 
𝑛𝑀 7 4 4 4 3 8 
 
The results of the simulations are shown in Table 11. For each test and each simulation 
case, the table value is power of detecting parallelism, which is the proportion of times among 
the 10,000 replicates that each test resulted in a declaration of parallelism. In case 1, the response 
curves are not exactly parallel but they are well within the equivalence limits, so we argue that 
they are approximately parallel. In this case, when the standard deviation of the two preparations 
was high, the classical design declared parallelism relatively rarely (16.89%), while the D-
optimal design with the same test method, declared parallelism a majority of the time (85.14%). 
Also, it’s true that the null hypotheses are easily rejected when the standard deviation is small. 
That is simulated data were closely distributed around the mean value and didn't change a lot. 
However, we could note that for a given value of σ, the proportion of declaring parallelism of D-
optimal design was always greater than that of classical design. So, whatever the sigma is high or 
low, it always showed that the D-optimal design provides the preferred inference.  
In case 2, the response curves are exactly parallel, and only the potency differs. In this 
case, the test with D-optimal design declared parallelism between 88.14% and 99.98% of the 
time. Because the null hypothesis for the test is true in this case, this means that the test 
maintained a rejection rate in a high level. For the both design approaches, the percentage of 
declaring parallelism increased as the standard deviation decreased. However, for standard 
23 
 
design, the proportion of rejecting hypothesizes decreased more greatly (from 87.62% to 
20.53%). Overall, the results from cases 1 and 2 suggest that tests to establish parallelism with 
classical design may be more sensitive to the standard deviation of the data than the tests with D-
optimal design. Even for small σ, still D-optimal design performs much better than classical 
design. 
In case 3, the ratios of the slopes and the lower and upper plateaus were all set on the 
boundary of the equivalence limits. For this case, the tests with D-optimal design never declared 
parallelism for any of the 10,000 simulation replicates, regardless of the value of standard 
deviation. Similarly, the tests with classical design almost never declared parallelism in this case. 
Since the null hypothesis is true in this case, this represents an empirical type I error rate of zero. 
The results confirm that changing design approach would not affect the rejection ratio when the 
dose-response curves are not parallelism. 
In case 4, the ratio of the lower plateaus was set just outside the equivalence limits (
𝑎1
𝑎2
=
0.75), while the slopes and the upper plateaus were equal. Similarly, in case 5 the ratio of the 
slopes was outside the equivalence limits (
𝑏1
𝑏2
= 1.29), but the upper and lower plateaus were 
equal. For both these cases, the both tests seldom declared parallelism regardless of the value of 
standard deviation, with a maximum rate of only 0.45% for classical design and 0.47% for D-
optimal design. Since null hypothesis is true in this case, the proportions are less than type I error 
rates (0.05).  
Overall, the simulation results indicate that the IUT with the modified D-optimal design 
for equivalence works better in all cases than with the classical design. The modified D-optimal 
design appears to be clearly more effective in the cases illustrated by the examples: precise 
assays where the true response curves are approximately or exactly parallel, and assays where 
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the standard deviation is relatively high. It is more likely that the true curves will be only 
approximately parallel with high standard deviation in practical situations, and thus it will be 
much more efficient to use the modified D-optimal design for testing parallelism in practice. 
Table 11. The power for D-optimal design and Classical design 
σ  0.04 0.05 0.06 0.07 
Case 1: parallel 
Classical 0.8554 0.6069 0.3476 0.1689 
D-optimal 0.9996 0.991 0.9481 0.8514 
Case 2: Exactly parallel 
Classical 0.8762 0.6462 0.3913 0.2053 
D-optimal 0.9998 0.9928 0.9548 0.8814 
Case 3: 
Boundary 
Values 
Classical 0 0 0 0 
D-optimal 0 0 0 0 
Case 4: 
Unequal lower 
plateaus 
Classical 0.006 0.0045 0.0014 0.0006 
D-optimal 0.0008 0.0019 0.0047 0.0036 
Case 5: Unequal slopes 
Classical 0.0006 0 0 0 
D-optimal 0.0047 0.005 0.0029 0.0003 
 
  
25 
 
5. SUMMARY 
In this article, the problem of testing the parallelism of the response curves for a test 
preparation and a standard preparation using the 4PL model was discussed. we argued that the 
problem may be more accurately detected by IUT with implementing the D-optimal design. This 
result is obtained through comparing the ratio of rejecting null hypothesis, which can be readily 
constructed using the output from standard nonlinear regression software. The IUT was easily 
implemented by using a sequence of one-sided approximate t-tests, and rejecting the null 
hypothesis established evidence in favor of practically parallel response curves. 
D-optimal design minimizes the variance of parameter estimated, so it appeared to be 
clearly more effective.  The simulation results suggested that the modified D-optimal design 
indeed provides precise results of testing parallelism in the situations that the true response 
curves are indeed exactly or approximately parallel. The classical design does not help very 
much for reducing the variance of estimating the parameters while the D-optimal design does. 
The classical design becomes more problematic when there is large variance in the dataset. In the 
simulation cases where the true response curves were clearly nonparallel, both designs failed to 
support parallelism the vast majority of the time. As we have noted before, approximately 
parallel lines with high standard deviation are more likely to be tested in practice and this study 
suggests to use that the modified D-optimal design can be employed for testing parallelism in 
real bioassay. 
A potential question is that we just used one test method to compare the D-optimal design 
and the classical design. Thus, further study is recommended to contrast the two designs in other 
testing methods, such F test or chi-square test. 
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APPENDIX A. R CODES FOR T-VALUES OF CLASSICAL DESIGN  
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2.02,-1.42,2.31,10.12) 
 pa2<-c(2.04,-1.35,2.59,10.12) 
 x11<-seq(1.1,3.8,0.3) 
 px1<-rep(x11,3) 
pe1<-rnorm(30,0,0.04) 
 y11<-Y(pa1,px1,pe1) #ten-dose test 
pe2<-rnorm(30,0,0.04) 
y12<-Y(pa2,px1,pe2) #ten-dose control 
m<-nls(y11~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12)) 
(tm<-summary(m)) 
n<-nls(y12~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86)) 
(tn<-summary(n)) 
#toxicityassay 
pa3<-c(16.44,0.83,6.35,85.19) 
pa4<-c(13.61,0.82,6.83,93.01) 
x21<-seq(3.5,9,0.5) 
px2<-c(x21,x21,x21) 
e31<-rnorm(12,0,1.4) 
e32<-rnorm(12,0,1.4) 
e33<-rnorm(12,0,1.4) 
pe3<-c(e31,e32,e33) 
y21<-Y(pa3,px2,pe3) #toxicity control 
e41<-rnorm(12,0,1.4) 
e42<-rnorm(12,0,1.4) 
e43<-rnorm(12,0,1.4) 
pe4<-c(e41,e42,e43) 
y22<-Y(pa4,px2,pe4) #toxicity test 
p<-nls(y21~a+(d-a)/(1+exp(b*(c-px2))),start=list(a=16.44,b=0.83,c=6.35,d=85.19)) 
(tp<-summary(p)) 
q<-nls(y22~a+(d-a)/(1+exp(b*(c-px2))),start=list(a=13.61,b=0.82,c=6.83,d=93.01)) 
(tq<-summary(q)) 
Dl=0.8 
Du=1.25 
T1=seq(3) 
T2=seq(3) 
 for(i in 1:4){ 
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T1[i]=(abs(tm$coefficients[i,1])-
Dl*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Dl^2*tn$coefficients[i,2]^2) 
T2[i]=(abs(tm$coefficients[i,1])-
Du*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Du^2*tn$coefficients[i,2]^2) 
} 
T1 
T2 
TT1=seq(3) 
TT2=seq(3) 
 for(i in 1:4){ 
TT1[i]=(tp$coefficients[i,1]-
Dl*tq$coefficients[i,1])/sqrt(tp$coefficients[i,2]^2+Dl^2*tq$coefficients[i,2]^2) 
TT2[i]=(tp$coefficients[i,1]-
Du*tq$coefficients[i,1])/sqrt(tp$coefficients[i,2]^2+Du^2*tq$coefficients[i,2]^2) 
} 
TT1 
TT2  
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APPENDIX B. R CODES FOR T-VALUES OF D-OPTIMAL DESIGN 
library("VNM") 
Design1<- MOPT(LB = 1, UB = 4, P = c(2.02, 8.10, 10.07, -1.42),lambda = c(1,0), delta = -1, 
r = 30, verbose = TRUE) 
Design2<- MOPT(LB = 1, UB = 4, P = c(2.04, 7.82, 13.33, -1.35),lambda = c(1,0), delta = -1, 
r = 30, verbose = TRUE) 
summary(Design1) 
summary(Design2) 
library("VNM") 
Design1<- MOPT(LB = 3.5, UB = 9, P = c(16.44, 68.75, 572.49, 0.83),lambda = c(1,0), delta 
= 1, r = 36, verbose = TRUE) 
Design2<- MOPT(LB = 3.5, UB = 9, P = c(13.61, 79.4, 925.19, 0.82),lambda = c(1,0), delta = 
1, r = 36, verbose = TRUE) 
summary(Design1) 
summary(Design2) 
##case2## 
Design1<- MOPT(LB = 1, UB = 4, P = c(2, 8, 9.97, -1.4),lambda = c(1,0), delta = -1, r = 30, 
verbose = TRUE) 
Design2<- MOPT(LB = 1, UB = 4, P = c(2, 8, 13.46, -1.4),lambda = c(1,0), delta = -1, r = 30, 
verbose = TRUE) 
summary(Design1) 
summary(Design2) 
##case3## 
Design1<- MOPT(LB = 1, UB = 4, P = c(1.6, 6.4, 9.97, -1.5),lambda = c(1,0), delta = -1, r = 
30, verbose = TRUE) 
Design2<- MOPT(LB = 1, UB = 4, P = c(2, 8, 13.46, -1.2),lambda = c(1,0), delta = -1, r = 30, 
verbose = TRUE) 
summary(Design1) 
summary(Design2) 
##case4## 
Design1<- MOPT(LB = 1, UB = 4, P = c(1.5, 8.5, 9.97, -1.4),lambda = c(1,0), delta = -1, r = 
30, verbose = TRUE) 
Design2<- MOPT(LB = 1, UB = 4, P = c(2, 8, 13.46, -1.4),lambda = c(1,0), delta = -1, r = 30, 
verbose = TRUE) 
summary(Design1) 
summary(Design2) 
case##case5## 
Design1<- MOPT(LB = 1, UB = 4, P = c(2, 8, 9.97, -1.5),lambda = c(1,0), delta = -1, r = 30, 
verbose = TRUE) 
Design2<- MOPT(LB = 1, UB = 4, P = c(2, 8, 13.46, -1.16),lambda = c(1,0), delta = -1, r = 30, 
verbose = TRUE) 
summary(Design1) 
summary(Design2) 
############################################## 
Y<-function(par,x,e){ 
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n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2.02,-1.42,2.31,10.12) 
 pa2<-c(2.04,-1.35,2.59,9.86) 
dx1<-c(rep(1,7),rep(1.88,1),rep(1.89,3),rep(1.99,4),rep(2.95,4),rep(3.08,3),rep(4,8)) 
Dl=0.8 
Du=1.25 
r_d=0 
total=0 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
 e11<-rnorm(20,0,0.04) 
 e12<-rnorm(20,0,0.04) 
 e13<-rnorm(20,0,0.04) 
 pe1<-c(e11,e12,e13) 
 dy11<-Y(pa1,dx1,pe1) #test 
e21<-rnorm(20,0,0.05) 
e22<-rnorm(20,0,0.05) 
e23<-rnorm(20,0,0.05) 
pe2<-c(e21,e22,e23) 
dy12<-Y(pa2,dx1,pe2) #control 
 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86),control = 
list(maxiter = 100)) 
tdn<-summary(dn) 
dT1=seq(4) 
dT2=seq(4) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
########################################## 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
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Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
pa1<-c(16.44,0.83,6.35,85.19) 
pa2<-c(13.61,0.82,6.83,93.01) 
dx1<-c(rep(3.5,18),rep(5.35,9),rep(5.56,9),rep(7.25,9),rep(7.46,9),rep(9,18)) 
Dl=0.8 
Du=1.25 
r_d=0 
total=0 
t1<-qt(0.05,64,lower.tail = FALSE) 
t2<-qt(0.05,64) 
 e11<-rnorm(24,0,1.6) 
 e12<-rnorm(24,0,1.6) 
 e13<-rnorm(24,0,1.6) 
 pe1<-c(e11,e12,e13) 
 dy11<-Y(pa1,dx1,pe1) #test 
e21<-rnorm(24,0,1.6) 
e22<-rnorm(24,0,1.6) 
e23<-rnorm(24,0,1.6) 
pe2<-c(e21,e22,e23) 
dy12<-Y(pa2,dx1,pe2) #control 
 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=16.44,b=0.83,c=6.35,d=85.19),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=13.61,b=0.82,c=6.83,d=93.01),control 
= list(maxiter = 100)) 
tdn<-summary(dn) 
dT1=seq(4) 
dT2=seq(4) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
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APPENDIX C. R CODES FOR POWER OF CLASSICAL DESIGN 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2.02,-1.42,2.31,10.12) 
 pa2<-c(2.04,-1.35,2.59,10.12) 
 x11<-seq(1.1,3.8,0.3) 
 px1<-rep(x11,3) 
Dl=0.8 
Du=1.25 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
T1=seq(3) 
T2=seq(3) 
r=0 
a=0 
total=0 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.07) 
 y11<-Y(pa1,px1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.07) 
y12<-Y(pa2,px1,pe2) #ten-dose test 
m<-nls(y11~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12)) 
tm<-summary(m) 
n<-nls(y12~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86)) 
tn<-summary(n) 
 for(i in 1:4){ 
T1[i]=(abs(tm$coefficients[i,1])-
Dl*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Dl^2*tn$coefficients[i,2]^2) 
T2[i]=(abs(tm$coefficients[i,1])-
Du*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Du^2*tn$coefficients[i,2]^2)} 
total=total+1 
if(T1[1]>t1 & T1[2]>t1 & T1[4]>t1 & T2[1]<t2 & T2[2]<t2 & T2[4]<t2){ 
r=r+1} 
} 
(power_no<-r/total) 
#################################################################### 
#case2 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
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for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2,-1.4,2.3,10) 
 pa2<-c(2,-1.4,2.6,10) 
 x11<-seq(1.1,3.8,0.3) 
 px1<-rep(x11,3) 
Dl=0.8 
Du=1.25 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
T1=seq(3) 
T2=seq(3) 
r=0 
a=0 
total=0 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.07) 
 y11<-Y(pa1,px1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.07) 
y12<-Y(pa2,px1,pe2) #ten-dose test 
m<-nls(y11~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12)) 
tm<-summary(m) 
n<-nls(y12~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86)) 
tn<-summary(n) 
 for(i in 1:4){ 
T1[i]=(abs(tm$coefficients[i,1])-
Dl*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Dl^2*tn$coefficients[i,2]^2) 
T2[i]=(abs(tm$coefficients[i,1])-
Du*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Du^2*tn$coefficients[i,2]^2)} 
total=total+1 
if(T1[1]>t1 & T1[2]>t1 & T1[4]>t1 & T2[1]<t2 & T2[2]<t2 & T2[4]<t2){ 
r=r+1} 
} 
(power_no<-r/total) 
#################################################################### 
#case3 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(1.6,-1.5,2.3,8) 
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 pa2<-c(2,-1.2,2.6,10) 
 x11<-seq(1.1,3.8,0.3) 
 px1<-rep(x11,3) 
Dl=0.8 
Du=1.25 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
T1=seq(3) 
T2=seq(3) 
r=0 
a=0 
total=0 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.04) 
 y11<-Y(pa1,px1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.04) 
y12<-Y(pa2,px1,pe2) #ten-dose test 
m<-nls(y11~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12)) 
tm<-summary(m) 
n<-nls(y12~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86)) 
tn<-summary(n) 
 for(i in 1:4){ 
T1[i]=(abs(tm$coefficients[i,1])-
Dl*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Dl^2*tn$coefficients[i,2]^2) 
T2[i]=(abs(tm$coefficients[i,1])-
Du*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Du^2*tn$coefficients[i,2]^2)} 
total=total+1 
if(T1[1]>t1 & T1[2]>t1 & T1[4]>t1 & T2[1]<t2 & T2[2]<t2 & T2[4]<t2){ 
r=r+1} 
} 
(power_no<-r/total) 
#################################################################### 
#case4 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(1.5,-1.4,2.3,10) 
 pa2<-c(2,-1.4,2.6,10) 
 x11<-seq(1.1,3.8,0.3) 
 px1<-rep(x11,3) 
Dl=0.8 
Du=1.25 
36 
 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
T1=seq(3) 
T2=seq(3) 
r=0 
a=0 
total=0 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.07) 
 y11<-Y(pa1,px1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.07) 
y12<-Y(pa2,px1,pe2) #ten-dose test 
m<-nls(y11~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12)) 
tm<-summary(m) 
n<-nls(y12~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86)) 
tn<-summary(n) 
 for(i in 1:4){ 
T1[i]=(abs(tm$coefficients[i,1])-
Dl*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Dl^2*tn$coefficients[i,2]^2) 
T2[i]=(abs(tm$coefficients[i,1])-
Du*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Du^2*tn$coefficients[i,2]^2)} 
total=total+1 
if(T1[1]>t1 & T1[2]>t1 & T1[4]>t1 & T2[1]<t2 & T2[2]<t2 & T2[4]<t2){ 
r=r+1} 
} 
(power_no<-r/total) 
#################################################################### 
#case5 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2,-1.5,2.3,10) 
 pa2<-c(2,-1.16,2.6,10) 
 x11<-seq(1.1,3.8,0.3) 
 px1<-rep(x11,3) 
Dl=0.8 
Du=1.25 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
T1=seq(3) 
T2=seq(3) 
r=0 
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a=0 
total=0 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.06) 
 y11<-Y(pa1,px1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.06) 
y12<-Y(pa2,px1,pe2) #ten-dose test 
m<-nls(y11~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12)) 
tm<-summary(m) 
n<-nls(y12~a+(d-a)/(1+exp(b*(c-px1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86)) 
tn<-summary(n) 
 for(i in 1:4){ 
T1[i]=(abs(tm$coefficients[i,1])-
Dl*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Dl^2*tn$coefficients[i,2]^2) 
T2[i]=(abs(tm$coefficients[i,1])-
Du*abs(tn$coefficients[i,1]))/sqrt(tm$coefficients[i,2]^2+Du^2*tn$coefficients[i,2]^2)} 
total=total+1 
if(T1[1]>t1 & T1[2]>t1 & T1[4]>t1 & T2[1]<t2 & T2[2]<t2 & T2[4]<t2){ 
r=r+1} 
} 
(power_no<-r/total)  
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APPENDIX D. R CODES FOR POWER OF D-OPTIMAL DESIGN 
#case1# 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2.02,-1.42,2.31,10.12) 
 pa2<-c(2.04,-1.35,2.59,10.12) 
dx1<-c(rep(1,7),rep(1.88,1),rep(1.89,3),rep(1.99,4),rep(2.95,4),rep(3.08,3),rep(4,8)) 
Dl=0.8 
Du=1.25 
r_d=0 
total=0 
dT1=seq(4) 
dT2=seq(4) 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.07) 
 dy11<-Y(pa1,dx1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.07) 
dy12<-Y(pa2,dx1,pe2) #ten-dose test 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86),control = 
list(maxiter = 100)) 
tdn<-summary(dn) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
total=total+1 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
} 
(power_d<-r_d/total) 
######################################################## 
#case2 
Y<-function(par,x,e){ 
n<-length(x) 
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Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(2,-1.4,2.3,10) 
 pa2<-c(2,-1.4,2.6,10) 
dx1<-c(rep(1,7),rep(1.88,4),rep(2.01,4),rep(2.95,4),rep(3.08,3),rep(4,8)) 
Dl=0.8 
Du=1.25 
r_d=0 
total=0 
dT1=seq(4) 
dT2=seq(4) 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.04) 
 dy11<-Y(pa1,dx1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.04) 
dy12<-Y(pa2,dx1,pe2) #ten-dose test 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86),control = 
list(maxiter = 100)) 
tdn<-summary(dn) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
total=total+1 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
} 
(power_d<-r_d/total) 
######################################################## 
#case3 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
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 pa1<-c(1.6,-1.5,2.3,8) 
 pa2<-c(2,-1.2,2.6,10) 
dx1<-c(rep(1,7),rep(1.88,4),rep(1.97,4),rep(2.93,4),rep(3.10,3),rep(4,8)) 
Dl=0.8 
Du=1.25 
r_d=0 
total=0 
dT1=seq(4) 
dT2=seq(4) 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.06) 
 dy11<-Y(pa1,dx1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.06) 
dy12<-Y(pa2,dx1,pe2) #ten-dose test 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86),control = 
list(maxiter = 100)) 
tdn<-summary(dn) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
total=total+1 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
} 
(power_d<-r_d/total) 
######################################################## 
#case4 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
 pa1<-c(1.5,-1.4,2.3,10) 
 pa2<-c(2,-1.4,2.6,10) 
dx1<-c(rep(1,7),rep(1.88,4),rep(2.01,4),rep(2.95,4),rep(3.08,3),rep(4,8)) 
Dl=0.8 
Du=1.25 
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r_d=0 
total=0 
dT1=seq(4) 
dT2=seq(4) 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.07) 
 dy11<-Y(pa1,dx1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.07) 
dy12<-Y(pa2,dx1,pe2) #ten-dose test 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86),control = 
list(maxiter = 100)) 
tdn<-summary(dn) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
total=total+1 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
} 
(power_d<-r_d/total) 
par(mfrow=c(1,2)) 
plot(dx1,dy11,col="red") 
plot(dx1,dy12,col="green") 
######################################################## 
#case5 
Y<-function(par,x,e){ 
n<-length(x) 
Y<-rep(0,n) 
for(i in 1:n){ 
Y[i]<-par[1]+(par[4]-par[1])/(1+exp(par[2]*(par[3]-x[i])))+e[i]} 
 return(Y)} 
# ten-dosebioassay 
  pa1<-c(2,-1.5,2.3,10) 
 pa2<-c(2,-1.16,2.6,10) 
dx1<-c(rep(1,7),rep(1.88,4),rep(1.96,4),rep(2.93,4),rep(3.10,3),rep(4,8)) 
Dl=0.8 
Du=1.25 
r_d=0 
total=0 
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dT1=seq(4) 
dT2=seq(4) 
t1<-qt(0.05,52,lower.tail = FALSE) 
t2<-qt(0.05,52) 
for(j in 1:10000){ 
 pe1<-rnorm(30,0,0.04) 
 dy11<-Y(pa1,dx1,pe1) #ten-dose control 
pe2<-rnorm(30,0,0.04) 
dy12<-Y(pa2,dx1,pe2) #ten-dose test 
dm<-nls(dy11~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.02,b=-1.42,c=2.31,d=10.12),control 
= list(maxiter = 100)) 
tdm<-summary(dm) 
dn<-nls(dy12~a+(d-a)/(1+exp(b*(c-dx1))),start=list(a=2.04,b=-1.35,c=2.59,d=9.86),control = 
list(maxiter = 100)) 
tdn<-summary(dn) 
 for(i in 1:4){ 
dT1[i]=(abs(tdm$coefficients[i,1])-
Dl*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Dl^2*tdn$coefficients[i,2]^2) 
dT2[i]=(abs(tdm$coefficients[i,1])-
Du*abs(tdn$coefficients[i,1]))/sqrt(tdm$coefficients[i,2]^2+Du^2*tdn$coefficients[i,2]^2)} 
total=total+1 
if(dT1[1]>t1 & dT1[2]>t1 & dT1[4]>t1 & dT2[1]<t2 & dT2[2]<t2 & dT2[4]<t2){ 
r_d=r_d+1} 
} 
(power_d<-r_d/to 
